# PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

> **NCT03149549** · PHASE1,PHASE2 · TERMINATED · sponsor: **CytomX Therapeutics** · enrollment: 99 (actual)

## Conditions studied

- Solid Tumor, Adult
- Breast Cancer
- Non Small Cell Lung Cancer
- Head and Neck Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** CX-2009

## Key facts

- **NCT ID:** NCT03149549
- **Lead sponsor:** CytomX Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-01
- **Primary completion:** 2020-09-10
- **Final completion:** 2020-09-10
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** Covid Pandemic; Business Decision to separate Phase 2 to new study
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149549, "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03149549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*